Tag: #biotech-funding5 results
Lemang Bio secured nearly 200M RMB in funding led by Yuecai Zhongyin and XtalPi to advance low-dose metabolic enhanced CAR-T clinical trials and production. The META 10 and META 10-AI platforms enable T-cell metabolic reprogramming for superior efficacy at ultra-low doses. Key progress includes CD19 CAR-T IND filing and IIT results showing 100% CR in B-ALL.
Cardiff-based biotech Antiverse raised $9.3M in Series A funding to expand its AI-powered platform for therapeutic antibody discovery. Led by Soulmates Ventures, the round includes Innovation Investment Capital, DOMiNO Ventures, and existing investors. Funds will advance lead programs to in vivo studies.
XtalPi reports 2025 revenue of 8B RMB, up 200%, with first profit of 2.58B RMB and 70B cash reserves. Focuses on automation labs and AI agents for stable revenue over pure algorithms. Cautious on clinical trials amid AI pharma boom.
London startup Epoch Biodesign secured $12M to scale AI-engineered enzymes that recycle nylon 6,6 waste into monomers with over 90% recovery. This eliminates virgin petroleum needs for leggings, airbags, and carpets. Total funding now surpasses $50M.
Insight Tech raised Pre-A funding led by Lenovo Ventures and launched SpectAlpha solid-state nanopore detector in June 2025. The product has been adopted by Peking University, Tsinghua, and 30+ top hospitals for clinical apps like 30-min pathogen detection. Company uses ML data training to boost sequencing accuracy, with neuromorphic potential.